Posted by Terry8 on May 4, 2011, at 12:25:22
In reply to Re: This study seems to cast a shadow on med combos..., posted by Phillipa on May 4, 2011, at 10:55:46
> I feel it's interesting that the funding seems to be both by NIMH and the dug companies. Phillipa
The funding was by NIMH. The drug companies simply provided the drugs. And even if they had also provided funding, it's not like the results being reported benefit the drug companies.
From what I understand, their results only address combos versus monotherapy as a first-line treatment. I wasn't aware that it was even that common to prescribe more than one AD as a first-line treatment. I'll be more intrigued when I see results that address monotherapy versus combos for treatment resistant cases, which is when you see combos being used more often.
poster:Terry8
thread:984479
URL: http://www.dr-bob.org/babble/20110502/msgs/984540.html